What about the company Vertex didn’t buy?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with what is my final edition of The Readout on my last day at STAT. I’ve had a wonderful time covering biotech here these last eight years, and that’s in no small part a testament to the clever and engaged readers of this very newsletter. Meghana Keshavan isn’t going anywhere, and starting soon you’ll be reading a new voice in your inbox. Thanks for reading, and have a great weekend.

The need-to-know this morning

• European regulators find no evidence of a link between new obesity medicines and suicidal thoughts.

Is biotech getting stale?

How would you spend $13 billion in cash? And remember Dendreon?

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In